Price movement over the last 24 hours
Affirm Holdings Inc vs TransMedics Group Inc — how do they compare? Affirm Holdings Inc trades at $80.69 (market cap $28.00B), while TransMedics Group Inc trades at $70.23 (market cap $2.46B). The key difference: Affirm Holdings Inc is far larger — about 11.4× TransMedics Group Inc's market cap, and Affirm Holdings Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| AFRM | TMDX | |
|---|---|---|
Market Cap | $28.00B | $2.46B |
Sector | Financials | Technology |
52-Week High | $92.18 | $150.42 |
52-Week Low | $42.53 | $61.99 |
Enterprise Value | $34.61B | $2.86B |
Signals from Pluang's Aura AI — not financial advice
AFRM trades at $83.62, down 1.14% on the day, with a bullish technical outlook supported by moving averages and a golden cross pattern. The company reported strong revenue growth, reaching $3.22 billion in 2025, and has consistently beaten earnings expectations in recent quarters. Recent partnerships with Bed Bath & Beyond and Backcountry expand its merchant network, driving transaction volume growth.
The outlook remains positive with analyst consensus favoring a buy rating and a $89 price target, though high valuation multiples and overbought RSI levels pose near-term risks. Earnings growth and BNPL market expansion are key catalysts, while credit losses and competition represent ongoing challenges for shareholders.
TMDX trades at $71.23, up 3.44% on the day, but technical indicators signal a bearish trend. The company reported strong profitability with a 27.04% net income margin and 45.22% ROE for 2025, though Q1 2026 earnings missed expectations. Recent strategic investments in European organ logistics aim to expand its competitive moat, but margin pressure from expansion costs is a key concern noted by analysts (Zacks Investment Research, 2026-07-07).
The investment outlook is mixed: strong analyst consensus (75% buy ratings) and a $108.71 price target suggest significant upside, but near-term execution risks and bearish technicals warrant caution. Long-term growth drivers in transplant logistics are compelling, yet investors must weigh expansion costs against the potential for market share gains.
Trailing returns across standard periods
Latest headlines on both assets
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →